Forbion

Forbion portfolio company Tessellate BIO, a preclinical-stage biotechnology company pioneering innovative Synthetic Lethality approaches in precision oncology, has appointed Dr. Lara Boyd as their new Chief Business Officer. With her extensive experience in biotech business strategy and partnerships, Dr. Boyd is set to play a pivotal role in driving Tessellate’s mission to bring groundbreaking treatments to patients in need. Her leadership will be invaluable as Tessellate continues to advance its pipeline and strengthen its position in the field of targeted cancer therapies. Congratulations to Dr. Lara Boyd and the entire Tessellate Bio team on this new chapter. Click on the following link to read more: https://lnkd.in/esj3Xnav #moversandshakers #portfoliocompany Rogier Rooswinkel Marc-Olivier Turgeon

Forbion is thrilled to support portfolio company SynOx Therapeutics as it advances in the fight against Tenosynovial Giant Cell Tumour (TGCT), a rare and debilitating disease. The company announced the completion of an extension to its Series B financing, bringing the total raised to an impressive $92 million. This funding is advancing the TANGENT study, SynOx’s pivotal Phase 3 clinical trial for emactuzumab, a CSF-1 receptor (CSF-1R) inhibiting monoclonal antibody that has the potential to be best-in-class for TGCT treatment. The TANGENT study has officially dosed its first patients and will be conducted globally across multiple centers. With a rigorous, randomized, double-blind, placebo-controlled design, the trial will evaluate overall response rate, functional and quality of life improvements, tumour volume impact, and response duration in approximately 130 patients. We are inspired by SynOx’s commitment to transforming TGCT treatment and look forward to sharing updates from this promising trial. For more details about TANGENT go to ClinicalTrials.gov identifier: NCT05417789 Click on the following link to learn more: https://lnkd.in/eHANaNMc #Forbion #SynOxTherapeutics #SeriesB #TGCT #Biotech #ClinicalTrials #HealthcareInnovation #lifesciences #biotech Dirk Kersten Audrey Cacaly

Forbion portfolio company Noema Pharma has dosed its first patients in a global Phase 2b study for gemlapodect (NOE-105), a pioneering, first-in-class investigational therapy aimed at treating Tourette syndrome. This critical study will assess the safety and efficacy of gemlapodect, marking a significant step forward in developing innovative treatment options for individuals with Tourette. Based in Basel, Switzerland, Noema Pharma continues to advance its neuroscience-focused pipeline with impactful therapies that address unmet needs for patients worldwide. We congratulate the Noema Pharma team on reaching this important milestone and look forward to seeing their continued progress. Click on the following link to learn more: https://lnkd.in/eKMAsZaC #biotech #lifesciences #neuroscience Nanna Lüneborg Audrey Cacaly

Join us in congratulating Professor Alberto Auricchio, founder and Chief Scientific Officer (CSO) of Forbion portfolio company AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, on his appointment as President and Board member of the European Society of Gene and Cell Therapy (ESGCT). The ESGCT Board is composed of researchers and clinicians representing a broad range of European Countries. Members are elected by nomination and vote at the Annual General Meeting. Election to the Board of ESGCT recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. Click on the following link to read more: https://lnkd.in/ecNXyxYe #appointment #lifesciences #venturecapital #biotech #news #portfolio #portfoliocompany Dr. Dmitrij Hristodorov Tim Lohoff, Ph.D.

Exciting news that our portfolio company Noema Pharma, a clinical-stage neuroscience-based biotech, has achieved significant progress in its mission to treat debilitating central nervous system (CNS) disorders. Today, Noema announced that the Phase 2a ALLEVIA-1 study with NOE-105 (gemlapodect) in patients with Tourette syndrome successfully met its primary and all key secondary endpoints. This achievement marks an important step forward for patients affected by Tourette syndrome and highlights the potential of innovative approaches in neuroscience. Congratulations to the entire Noema Pharma team. We are excited to continue supporting your journey to transform the landscape of CNS treatment. Click on the following link to learn more: https://lnkd.in/ebYmHaYX #Forbion #NoemaPharma #Neuroscience #TouretteSyndrome #CNS #Biotech #Innovation #LifeSciences #Biotech Nanna Lüneborg Audrey Cacaly

An exciting day for us today as we host our investors for our Annual Investor Meeting in Amsterdam. This year we were immensely proud to launch our newest effort: The Forbion EU Impact Roundtable to our LPs. In this inaugural session we focused on "Empowering Women's Health in 2024." In a gathering that got together diverse leaders from pharma, venture capital, academia and NGOs, the panel discussed the state of research in women's health and how to pave a way forward. A huge thank you to our panelists Mary Kerr, CEO of NeRRe Therapeutics Ltd, Kelle Moley, Global VP of Clinical & Translational R&D, Reproductive Medicine & Maternal Health at Ferring Pharmaceuticals, Diana Torgersen Head of Innovation Ecosystem Integration at Organon and Trine Bartholdy, Chief Business Officer at BioInnovation Institute. We are grateful for their insights and commitment to advancing women's health. Stay tuned for the full session recording. #Forbion #ImpactRoundtable #WomensHealth #VentureCapital #Pharma #InvestingInImpact #biotech

Forbion Raises Over €2 Billion Across Two New Funds, Bringing Total Assets Under Management to €5 Billion   We are thrilled to announce our largest fundraising to date, securing over €2 billion ($2.2 billion) for two new funds. Forbion Growth Opportunities Fund III closed at €1.2 billion ($1.3 billion), and Forbion Ventures Fund VII raised €890 million ($980 million), bringing our total assets under management to €5 billion ($5.5 billion). This significant fundraising follows a period of outstanding performance, with six recent exits valued at over $1 billion each. Forbion’s continued growth reflects our commitment to supporting and building life sciences companies that drive impactful change across the healthcare landscape. We look forward to leveraging this new capital to continue our mission of impacting the future of medicine. We are grateful for the trust and support from our investors as we work to accelerate innovation in the life sciences sector. Click on the following link to learn more: https://lnkd.in/eUrYVC2k #Forbion #LifeSciences #VentureCapital #Fundraising #HealthcareInnovation #Biotech #GrowthOpportunities #InvestingInInnovation 

Forbion is pleased to announce a new chapter for our portfolio company, Calluna Pharma. The company welcomes Mark Altmeyer as the incoming Chairman and Mark Gaffney as its incoming CEO. We would also like to thank John Montana for his leadership and dedication in building a strong foundation at Calluna Pharma. John will return to his role as an Operating Partner at Forbion. Click on the following link to learn more: https://lnkd.in/ezn5RaZF #biotech #pharma #forbion #portfolio #leadership #lifesciences #biotech

Forbion Proudly Backs Purespring Therapeutics in Series B Financing. Purespring Therapeutics has raised £80 million ($105 million) in an oversubscribed Series B financing round. The round was led by Sofinnova Partners, with collaboration from Gilde Healthcare, Forbion, British Patient Capital, and founding investor Syncona Limited . The funds will accelerate the advancement of Purespring’s AAV pipeline of gene therapy programs, which are set to revolutionize the treatment of kidney diseases. This includes the development of their lead program targeting IgA Nephropathy (IgAN), a serious kidney condition with unmet medical needs. We are excited to support Purespring in their journey to transform the field of gene therapy for kidney disease. #Lifesciences #biotech #kidneydiseases #SeriesB #financing Click the following link to learn more: https://lnkd.in/eYqDnrz3 Marco Boorsma Tim Lohoff, Ph.D. Gilles van Tienderen, PhD

We are thrilled to share that Mestag Therapeutics, a Forbion portfolio company, has entered into a license and research collaboration with MSD, a global leader in healthcare. This partnership leverages Mestag’s proprietary Reversing Activated Fibroblast Technology (RAFT) platform to identify new targets in the fight against inflammatory diseases. Through this collaboration, Mestag will deploy RAFT to interrogate the pathogenic role of fibroblasts, uncovering novel insights and drug targets. MSD will have the option to license these targets, aiming to drive forward the discovery, development, and commercialization of breakthrough therapeutics. Congratulations to the Mestag team on this significant milestone. We look forward to seeing the transformative potential this collaboration brings to the treatment of inflammatory diseases. Click on the following link to read the official company release: https://lnkd.in/eURDhksN Antoine Boulanger #lifesciences #biotech